Company
Zhuhai
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
0
Approvals since 2021
1
Originals and new uses
Phase 3 trials
6
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Beizray approved Oct 23, 2024
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- QA108 Phase III Study in Subjects With Intermediate AMDPivotal-lookingRecruiting
Smilebiotek Zhuhai LimitedIndustry
NCT07189169 · 400 participants (planned) · Start Jul 8, 2025 · Primary completion Mar 1, 2027
Drug: QA108 granules; QA108 granules placebo · For: Intermediate Age-Related Macular Degeneration
Sites: Beijing, China
- Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic RetinopathyPivotal-lookingRecruiting
Beletalent (Zhuhai) Pharmaceutical Co., LtdIndustry
NCT06817265 · 360 participants (planned) · Start Apr 29, 2025 · Primary completion Aug 30, 2026
Drug: TNTL; TNTL simulation preparation · For: Non-Proliferative Diabetic Retinopathy
Sites: Xuancheng, China; Beijing, China; Guangzhou, China · 30 sites in all
Marketed drugs (1)
Newest FDA action first.
- Beizray Docetaxel · 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.